OncoKB New Data Release - June 4, 2024
Contact OncoKB
Data Release v4.17
June 4, 2024
What's New
Release of OncoKB™ SOP v.4.0
Updated Therapeutic Implications:
New alteration(s) with a tumor type-specific level of evidence
Level 2: Pembrolizumab, Nivolumab, Ipilimumab + Nivolumab and Dostarlimab added as treatments for POLE Exonuclease Domain Missense Mutations (268_471mis) in colorectal cancer and small bowel cancer based on inclusion of aforementioned treatments in the NCCN Colon Cancer Guidelines V2.2024 and in Small Bowel Adenocarcinoma Guidelines V3.2024 (PMID: 26028255, 31682550, 28734759, 37917058; Abstract: Chae et al. Abstract# 3417, AACR 2020)
Level 2: Pembrolizumab, Nivolumab, Ipilimumab + Nivolumab and Dostarlimab added as treatments for POLD1 Exonuclease Domain Missense Mutations (304_533mis) in colorectal cancer and small bowel cancer based on inclusion of aforementioned treatments in the NCCN Colon Cancer Guidelines V2.2024 and in Small Bowel Adenocarcinoma Guidelines V3.2024 (PMID: 26028255, 31682550, 28734759, 37917058; Abstract: Chae et al. Abstract# 3417, AACR 2020)
Level 3A: AMG 193 and MRTX1719 added as treatments for MTAP Deletion in all solid tumors based on clinical trial data of AMG 193 and MRTX1719 in patients with MTAP-null solid tumors and supporting preclinical data (PMID: 37552839; Abstract: Rodon, J. et al. Abstract# PR006, AACR-NCI-EORTC 2023)
Addition of sensitivity-associated therapy(s) for an alteration(s) with a tumor type-specific resistance level of evidence
Level 2: Lorlatinib added as a treatment for ALK G1202R and L1196M in non-small cell lung cancer based on inclusion of lorlatinib in the NCCN Non-Small Cell Lung Cancer Guidelines V5.2024 (PMID: 30892989)
Resistance-associated evidence currently in OncoKB™ for ALK G1202R (Level R2 in NSCLC; Alectinib) and ALK L1196M (Level R2 in NSCLC; Crizotinib)
Addition of therapy(s) associated with a tumor type-specific leveled alteration(s) (without changing the alteration's highest level of evidence)
Level 2: Nivolumab, Ipilimumab + Nivolumab and Dostarlimab added as a treatment for MSI-H in small bowel cancer based on inclusion of aforementioned treatments in the NCCN Small Bowel Adenocarcinoma V3.2024 (PMID: 28734759, 37917058; Abstract: Chae et al. Abstract# 3417, AACR 2020)
Sensitivity-associated evidence currently in OncoKB™ for MSI-H (Level 1 in Small Bowel Cancer; Pembrolizumab)
Level R2: Crizotinib, Ceritinib and Brigatinib added as treatments with predictive resistance for ALK G1202R in non-small cell lung cancer based on patient response data and supporting preclinical evidence (PMID: 31358542, 29935304, 27432227, 24675041, 25727400, 26698910, 31585938, 22277784)
Resistance-associated evidence currently in OncoKB™ for ALK G1202R (Level R2 in NSCLC; Alectinib)
Removal of therapy(s) associated with a tumor type-specific leveled alteration(s) (without changing the alteration's highest level of evidence)
Level 1: Mobocertinib removed as a treatment for EGFR Exon 20 in-frame insertions in non-small cell lung cancer based on the voluntary withdrawal of mobocertinib due to the Phase III EXCLAIM-2 trial failing to meet its primary endpoint of PFS (Abstract: Jänne, PA. et al. Abstract# 507O, Annals of Oncol. 2023)
EGFR exon 20 insertions in NSCLC remain Level 1 in OncoKB™ in association with amivantamab and amivantamab + chemotherapy
Gene Curation:
Addition of 5 new genes:
We're Here to Help
As always, don’t hesitate to reach out if you have comments, questions or suggestions. We love to hear from you. You can reach us at con...@oncokb.org
